Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LY3522348, A New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy Adults

13 May 2025

Abstract excerpt

INTRODUCTION: This study aimed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of the ketohexokinase inhibitor LY3522348 in healthy participants. METHODS: This first-in-human phase 1 study evaluated LY3522348, a highly selective, oral dual inhibitor of human ketohexokinase (KHK) isoforms C and A. The study was conducted in two parts: a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Diet, Metabolism, and Disease
Share to Microbial Metabolites in Food Biotechnology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40358849
DOI: 10.1007/s13300-025-01752-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LY3522348, A New Ketohexokinase Inhibitor: A First-in-Human Study in Healthy AdultsPMID 40358849Read ↗

Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK)Semantic proximity Read ↗

Safety and efficacy of pharmacological inhibition of ketohexokinase in hereditary fructose intoleranceSemantic proximity Read ↗

New-Generation Glucokinase Activators: Potential Game-Changers in Type 2 Diabetes TreatmentSemantic proximity Read ↗

Rationale and protocol for a safety, tolerability and feasibility randomized, parallel group, double-blind, placebo-controlled, pilot study of a novel ketone ester targeting frailty via immunometabolic geroscience mechanismsSemantic proximity Read ↗

Daily consumption of ketone ester, bis-octanoyl (R)-1,3-butanediol, is safe and tolerable in healthy older adults, a randomized, parallel arm, double-blind, placebo-controlled, pilot studySemantic proximity Read ↗

The KHENERGY Study: Safety and Efficacy of KH176 in Mitochondrial m.3243A>G Spectrum Disorders.Semantic proximity Read ↗

Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review.Semantic proximity Read ↗

Effect of Food Intake on Pharmacokinetics of Oral Almonertinib: A Randomized Crossover Trial in Healthy Chinese Participants.Semantic proximity Read ↗

Glucagon/GLP-1 receptor co-agonist NNC9204-1177 reduced body weight in adults with overweight or obesity but was associated with safety issuesSemantic proximity Read ↗

Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.Semantic proximity Read ↗

Diazoxide improves hormonal counterregulatory responses to acute hypoglycemia in long-standing type 1 diabetes.Semantic proximity Read ↗

Alcohol metabolism and psychomotor function after consuming different alcoholic beverages: baijiu, beer and wine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.